Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: A multicenter phase II study

BMC Cancer

Volumn 7, Issue , 2007, Pages

  Emmanouilides, Christos ^a   Sfakiotaki, Georgia ^b   Androulakis, Nikolaos ^b   Kalbakis, Kostas ^b   Christophylakis, Charalambos ^c   Kalykaki, Antonia ^b   Vamvakas, Lambros ^b   Kotsakis, Athanasios ^b   Agelaki, Sofia ^b   Diamandidou, Eleni ^a   Touroutoglou, Nikolaos ^a   Chatzidakis, Adam ^b   Georgoulias, Vassilis ^b   Mavroudis, Dimitris ^b   Souglakos, John ^b  

^a INTERBALKAN MEDICAL CENTER   (Greece)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^c IASO GENERAL HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; ANTINEOPLASTIC AGENT; FOLFOX PROTOCOL; MONOCLONAL ANTIBODY; PLATINUM COMPLEX; UNCLASSIFIED DRUG;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER GROWTH; CANCER RELAPSE; CANCER SURGERY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL PROTOCOL; CLINICAL TRIAL; COLORECTAL CANCER; CONSTIPATION; CONTINUOUS INFUSION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSESTHESIA; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; LIVER METASTASIS; LUNG EMBOLISM; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PARESTHESIA; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PROTEINURIA; SIDE EFFECT; SUDDEN DEATH; THROMBOCYTOPENIA; ADJUVANT THERAPY; ADOLESCENT; CARCINOMA; COLORECTAL TUMOR; LIVER TUMOR; LUNG TUMOR; METASTASIS; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; ORGANOPLATINUM COMPOUNDS; PATIENT COMPLIANCE; TREATMENT OUTCOME;

EID: 34347236908     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-7-91     Document Type: Article

References (23)

1. Jemal A Murray T Samuels A Ghafoor A Ward E Thun MJ Cancer statistics, 2003 CA Cancer J Clin 2003 53 5-26 12568441
2. Parkin DM Bray F Ferlay J Pisani P Global cancer statistics, 2002 CA Cancer J Clin 2005 55 74-108 15761078
3. Grothey A Sargent D Goldberg RM Schmoll HJ Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment J Clin Oncol 2004 22 1209-1214 10.1200/JCO.2004.11.037 15051767
4. Douillard JY Cunningham D Roth AD Navarro M James RD Karasek P Jandik P Iveson T Carmichael J Alakl M Gruia G Awad L Rougier P Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial Lancet 2000 355 1041-1047 10.1016/S0140-6736(00)02034-1 10744089
5. Tournigand C Andre T Achille E Lledo G Flesh M Mery-Mignard D Quinaux E Couteau C Buyse M Ganem G Landi B Colin P Louvet C de GA FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study J Clin Oncol 2004 22 229-237 10.1200/ JCO.2004.05.113 14657227
6. Hurwitz HI Fehrenbacher L Hainsworth JD Heim W Berlin J Holmgren E Hambleton J Novotny WF Kabbinavar F Bevacizumab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer J Clin Oncol 2005 23 3502-3508 10.1200/JCO.2005.10.017 15908660
7. Kabbinavar FF Hambleton J Mass RD Hurwitz HI Bergsland E Sarkar S Combined analysis of efficacy: The addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer J Clin Oncol 2005 23 3706-3712 10.1200/JCO.2005.00.232 15867200
8. Kabbinavar FF Schulz J McCleod M Patel T Hamm JT Hecht JR Mass R Perrou B Nelson B Novotny WF Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial J Clin Oncol 2005 23 3697-3705 10.1200/ JCO.2005.05.112 15738537
9. Hurwitz H Fehrenbacher L Novotny W Cartwright T Hainsworth J Heim W Berlin J Baron A Griffing S Holmgren E Ferrara N Fyfe G Rogers B Ross R Kabbinavar F Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 2004 350 2335-2342 10.1056/ NEJMoa032691 15175435
10. Goldberg RM Gill S Recent phase III trials of fluorouracil, irinotecan, and oxaliplatin as chemotherapy for metastatic colorectal cancer Cancer Chemother Pharmacol 2004 54 Suppl 1 S57-S64 15309516
11. Goldberg RM Sargent DJ Morton RF Fuchs CS Ramanathan RK Williamson SK Findlay BP Pitot HC Alberts S Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: A North American Intergroup Trial J Clin Oncol 2006 24 3347-3353 10.1200/JCO.2006.06.1317 16849748
12. Giantonio BJ Catalano PJ Meropol NJ High dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. J Clin Oncol 2007 25 1539-1544 10.1200/ JCO.2006.09.6305 17442997
13. National Cancer Institute: Common toxicity criteria, Version 2, 1999 2006
14. Therasse P Arbuck SG Eisenhauer EA Wanders J Kaplan RS Rubinstein L Verweij J Van GM van Oosterom AT Christian MC Gwyther SG New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 2000 92 205-216 10.1093/jnci/92.3.205 10655437
15. E.L. K P. M Non-parametric estimation from incomplete observations J Am Stat Assoc 1958 53 457-481 10.2307/2281868
16. D.R. C The analysis of Biniary Data London, Methnen 1970
17. Kohne CH Cunningham D Di CF Glimelius B Blijham G Aranda E Scheithauer W Rougier P Palmer M Wils J Baron B Pignatti F Schoffski P Micheel S Hecker H Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: Results of a multivariate analysis of 3825 patients Ann Oncol 2002 13 308-317 10.1093/annonc/mdf034 11886010
18. Hurwitz H Kabbinavar F Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer Oncology 2005 69 Suppl 3 17-24 10.1159/000088480 16301832
19. Emmanouilides C Pegram M Robinson R Hecht R Kabbinavar F Isacoff W Anti-VEGF antibody bevacizumab (Avastin) with 5FU/LV as third line treatment for colorectal cancer Tech Coloproctol 2004 8 Suppl 1 s50-s52 10.1007/s10151-004-0110-4 15655642
20. Price N Bevacizumab improves the efficacy of 5-fluorouracil/leucovorin in patients with advanced colorectal cancer Clin Colorectal Cancer 2004 4 89-91 15285815
21. Kabbinavar F Hurwitz HI Fehrenbacher L Meropol NJ Novotny WF Lieberman G Griffing S Bergsland E Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer J Clin Oncol 2003 21 60-65 10.1200/ JCO.2003.10.066 12506171
22. Hochster HS Hart LL Ramanathan RK Hainsworth EE Childs BH Safety and efficacy of oxaliplatin/fluoropyrimidines regimens with or without bavacizumab as first-line treatment of metastatic colorectal cancer(mCRC): Final analysis of the TREE-study Proc ASCO 2006
23. Saltz LB Clarke E Diaz-Rubio E Scheithauer A Figer A Wong R Koski S Lichinitser M Yang T Cassidy J First efficacy and safety results from XELOX-1/NO16966, a randomised 2×2 factorial phase III trial of XELOX vs FOLFOX4 + bevacizumab or placebo in first-line metastatic colorectal cancer Proc GASTROINTESTINAL CANCER SYMPOSIUM 2007